Grail Inc Revenue Growth Rates (GRAL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Grail Inc   (NASDAQ: GRAL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

GRAL's Revenue Growth by Quarter and Year

Grail Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GRAL/growth
https://api.csimarket.com/api/v1/companies/GRAL/fundamentals
https://api.csimarket.com/api/v1/companies/GRAL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GRAL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 37.54
2nd Quarter June 44.69
1st Quarter March 40.79
FY 123.01





GRAL Revenue third quarter 2026 Y/Y Growth Comment
Grail Inc reported Revenue growth of 3.72% year on year in the third quarter 2026, to $ 37.54 millions, this is lower than Grail Inc 's recent average Revenue increase of 11.22%.

Looking into third quarter 2026 results within Medical Laboratories industry 11 other companies have achieved higher Revenue growth. While Grail Inc ' s Revenue increase of 3.72% ranks overall at the positon no. 838 in the third quarter 2026.


GRAL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.72 %
2nd Quarter June 25.75 %
1st Quarter March 28.11 %
FY   -

Financial Statements
Grail Inc 's third quarter 2026 Revenue $ 37.54 millions GRAL's Income Statement
Grail Inc 's third quarter 2025 Revenue $ 36.19 millions Quarterly GRAL's Income Statement


GRAL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -16.01 %
2nd Quarter June 9.56 %
1st Quarter March -6.44 %
FY (Year on Year)   -


Back to GRAL Growth rate Comparisons >> Back to GRAL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #178
Overall #838

Revenue Y/Y Growth Statistics
High Average Low
28.11 % 11.22 % -45.89 %
(Jun 30 2026)   (Sep 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #178
Overall #838
Revenue Y/Y Growth Statistics
High Average Low
28.11 % 11.22 % -45.89 %
(Jun 30 2026)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Grail Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
33.51 % 0.08 % -62.2 %
(Dec 31 2024)  


GRAL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Grail Inc disclosed fall in Revenue from the second quarter by -16.01% to $ 37.54 millions, from $ 44.69 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Grail Inc 's Revenue growth quarter on quarter, overall rank is 849.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #128
Overall #849
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #128
Overall #849
Revenue Q/Q Growth Statistics
High Average Low
33.51 % 0.08 % -62.2 %
(Dec 31 2024)  


GRAL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Grail Inc disclosed fall in Revenue from the second quarter by -16.01% to $ 37.54 millions, from $ 44.69 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Grail Inc 's Revenue growth quarter on quarter, overall rank is 849.


Grail Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 165.26
Y / Y Revenue Growth (TTM) 23.07 %
Year on Year Revenue Growth Overall Ranking # 3166
Seqeuential Revenue Change (TTM) 5.86 %
Seq. Revenue Growth (TTM) Overall Ranking # 2313


Cumulative Revenue growth Comment
With 23.07% annual Revenue growth, Grail Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 424 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2187 to 3166.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 425
Overall # 3166

Revenue TTM Y/Y Growth Statistics
High Average Low
23.07 %
 12.36 %
-10.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2313
Cumulative Revenue growth Comment
With 23.07% annual Revenue growth, Grail Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 424 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2187 to 3166.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 425
Overall # 3166

Revenue TTM Y/Y Growth Statistics
High Average Low
23.07 %
12.36 %
-10.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2313




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GRAL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tenet Healthcare Corp6.47%$ 6.466 millions
Phibro Animal Health Corporation6.32%$ 6.320 millions
Mettler toledo International Inc 6.27%$ 6.273 millions
Agilon Health Inc 5.86%$ 5.864 millions
Johnson and Johnson5.86%$ 5.860 millions
Stoke Therapeutics Inc 5.86%$ 5.860 millions
Genedx Holdings Corp 5.64%$ 5.642 millions
Adma Biologics Inc 5.59%$ 5.595 millions
Innoviva Inc 5.55%$ 5.551 millions
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions
Merck and Co Inc 4.68%$ 4.683 millions
Davita Inc 4.62%$ 4.617 millions
Sotera Health Company4.61%$ 4.613 millions
Avantor Inc 4.59%$ 4.588 millions
Icu Medical Inc4.39%$ 4.388 millions
Illumina Inc 4.15%$ 4.151 millions
Agenus Inc4.14%$ 4.144 millions
United Therapeutics Corporation4.13%$ 4.128 millions
Option Care Health Inc 4.09%$ 4.086 millions
Henry Schein Inc 3.95%$ 3.953 millions
Grail Inc 3.71%$ 3.705 millions
Docgo Inc 3.70%$ 3.702 millions
Hca Healthcare Inc 3.59%$ 3.591 millions
Collegium Pharmaceutical Inc 3.43%$ 3.427 millions
Healthcare Services Group Inc 3.29%$ 3.288 millions
Cytek Biosciences Inc 3.26%$ 3.255 millions
Zimmer Biomet Holdings Inc 3.07%$ 3.073 millions


About Grail Inc Revenue Growth Rates (GRAL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Grail Inc (CIK 1699031).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-071041
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Grail Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.